Company intelligence / Profile preview

Peroxitech

Philadelphia, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Peroxitech's lead candidate PIP-2 demonstrated lung protection, rescue, and 70% survival rate in pre-clinical ALI models versus 0% in placebo; currently advancing through IND-enabling studies with Phase 1 targeted for late 2025.[1][2]

Therapeutic areas: Pulmonology
Modalities: Peptide
Industry: Biotech

Drug pipeline

1 asset

PIP-2

Unknown

Beyond the preview

Go deeper on Peroxitech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peroxitech.

Explore the full profile